Mylan has withdrawn its marketing authorization application in the EU for generic Gilenya (fingolimod) capsules after the European Medicines Agency raised concerns that the company’s bioequivalence studies were “not reliable.”
The US firm also did not take “sufficient precautions” to prevent the formation of nitrosamines, known to be highly carcinogenic,...




